Medical information Clinical review pending

Transplant Testing

HLA DSASAB Class I IgG Antibodies With C1q Screen Test

This test detects antibodies against Class I HLA antigens, crucial for assessing transplant compatibility and monitoring potential rejection in organ transplant patients.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: Serum. Confirm specific volume and collection tube requirements with the laboratory before booking.
Results: Results are typically available within 10-12 days. Confirm exact turnaround time with the laboratory before booking.
Preparation: No special preparation is required for this test. Confirm with the laboratory before booking.

Test priceKSh 77,220

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the HLA DSASAB Class I IgG Antibodies With C1q Screen Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Patients awaiting organ transplantation.
✓Individuals with a history of transplant rejection.
✓Patients undergoing re-evaluation for transplant compatibility.
✓Monitoring post-transplant patients for antibody development.

In plain language

What this test helps you understand

This test helps assess the risk of transplant rejection by identifying antibodies against donor HLA antigens. It aids in determining transplant compatibility and guiding immunosuppressive therapy.

The HLA DSASAB Class I IgG Antibodies With C1q Screen Test is a vital diagnostic tool used in transplantation. It detects specific antibodies that may indicate an immune response against a transplanted organ. Understanding the results is crucial for managing patient care, especially for those who have undergone organ transplantation. This test helps determine the likelihood of transplant rejection by identifying HLA antibodies, informing decisions about immunosuppressive therapy and follow-up care. It measures IgG antibodies against Class I HLA antigens and screens for complement-binding antibodies, which can indicate a higher risk of rejection. This test is recommended for patients considering organ transplantation, those with a history of transplant rejection, or individuals being re-evaluated for transplant compatibility. Early identification of potential rejection helps guide treatment and improve transplant success rates. Results are typically available within 10-12 days. Discuss your results with your healthcare provider to understand their implications for your treatment plan. We offer convenient access across Kenya, including home sample collection.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo special preparation is required for this test. Confirm with the laboratory before booking.

SampleSerum. Confirm specific volume and collection tube requirements with the laboratory before booking.

MethodologyLuminex X-Map technology is used for this test.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test detects specific IgG antibodies against Class I HLA antigens. It may not detect all types of antibodies or predict all forms of transplant rejection. Results must be interpreted in the context of the patient's clinical history and other laboratory findings. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

This test detects IgG antibodies against Class I HLA antigens and screens for complement-binding antibodies (C1q), which can indicate a risk of transplant rejection.

This test is typically recommended for patients before or after organ transplantation, especially if there's a history of rejection or concerns about compatibility.

Results are generally available within 10-12 days, but this can vary. Please confirm the current turnaround time with the laboratory.

A positive result indicates the presence of antibodies that could potentially react against a transplanted organ, increasing the risk of rejection. Your doctor will interpret this in context.

No special preparation, such as fasting, is typically required for this test. However, please confirm with the laboratory before your appointment.

Insurance coverage varies. Please check with your insurance provider regarding coverage for this specific test.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp